Advertisement

Alpha-fetoprotein Secreting Neuroendocrine Carcinoma of the Liver: a Case Report and Literature Review

  • Yakup Bozkaya
  • U. Aydın
  • A. Avcı
  • D. Tuncer
  • E. Yılmaz
Case Report
  • 10 Downloads

Introduction

Neuroendocrine tumors (NETs) occur in organs and tissues that contain peptides and amine-producing cells with different hormonal profiles depending on the region in which they are originated [1, 2]. NETs mostly occur in the gastrointestinal and bronchopulmonary system, and they are mostly seen in rectum, jejunum/ileum, and pancreas in gastrointestinal system [3]. Hepatic neuroendocrine tumors are rarely seen, and low-grade carcinoid tumors constitute the majority of cases [4]. On the other hand, hepatic neuroendocrine carcinomas (hNECs) are high-grade tumors that are rarely observed [5].

Alpha-fetoprotein (AFP) is a glycoprotein secreted by the liver and fetal yolk sac during the gestational period [6]. Except for malign diseases such as hepatocellular carcinoma (HCC) and yolk sac tumors, AFP level increases during benign diseases such as chronic liver disease, viral hepatitis, and cirrhosis. Despite published reports showing increased AFP levels in patients with NET,...

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Refferences

  1. 1.
    Kloppel G, Heitz PU. Classification of normal and neoplastic neuroendocrine cells. Ann N Y Acad Sci. 1994;733:19–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014:13–27.CrossRefPubMedGoogle Scholar
  3. 3.
    Yao JC, Hassan M, Phan A, Dogohoy C, Mares JE, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRefPubMedGoogle Scholar
  4. 4.
    Maggard MA, O’Connell JB, Ko CY. Updated population based review of carcinoid tumors. Ann Surg 2004; 240: 117–22.Google Scholar
  5. 5.
    Park CH, Chung JW, Jang SJ, Chung MJ, Bang S, Park SW, et al. Clinical features and outcomes of primary hepatic neuroendocrine carcinomas. J Gastroenterol Hepatol. 2012;27(8):1306–11.CrossRefPubMedGoogle Scholar
  6. 6.
    Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest. 1956;8:174–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Shah T, Srirajaskanthan R, Bhogal M, Toubanakis C, Meyer T, Noonan A, et al. Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients. Br J Cancer 2008; 99(1):72–77.Google Scholar
  8. 8.
    Lokich JJ, Ganda OP, O’Hara CJ, et al. Alpha-fetoprotein associated with islet cell tumors. Am J Clin Oncol. 1987;10(2):133–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Tazi EM, Essadi I, M’rabti H, Errihani H. Hepatocellular carcinoma and high grade neuroendocrine carcinoma: a case report and review of the literature. World J Oncol. 2011;2:37.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Geneve: World Health Organization; 2010.Google Scholar
  11. 11.
    Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, et al. AJCC Cancer Staging Manual (8th). New York: Springer; 2017.CrossRefGoogle Scholar
  12. 12.
    Camargo ES, Viveiros Mde M, Correa Neto IJ, Robles L, Rezende MB. Primary hepatic carcinoid tumor: case report and literature review. Einstein (Sao Paulo). 2014;12(4):505–8.CrossRefGoogle Scholar
  13. 13.
    Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991–1002.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rückert R, Rückert J, Dörffel Y, Rudolph B, Müller J. Primary hepatic neuroendocrine tumor: successful hepatectomy in two cases and review of the literature. Digestion. 1999;60(2):110–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Akahoshi T, Higashi H, Tsuruta S, Tahara K, Matsumoto T, Takeuchi H, et al. Primary neuroendocrine carcinoma coexisting with hemangioma in the liver: report of a case. Surg Today. 2010;40(2):185–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Critchley M. Octreotide scanning for carcinoid tumours. Postgrad Med J. 1997;73:399–402.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lin CW, Lai CH, Hsu CC, Hsu CT, Hsieh PM, Hung KC, et al. Primary hepatic carcinoid tumor: a case report and review of the literature. Cases J. 2009;2(1):90.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Li-Ming W, An SL, Wu JX. Diagnosis and therapy of primary hepatic neuroendocrine carcinoma: clinical analysis of 10 cases. Asian Pac J Cancer Prev. 2014;15(6):2541–6.CrossRefGoogle Scholar
  19. 19.
    Li RK, Zhao J, Rao SX, Chen CZ, Zeng MS, Qiang JW. Primary hepatic neuroendocrine carcinoma: MR imaging findings including preliminary observation on diffusion-weighted imaging. Abdom Imaging. 2013;38:1269–76.CrossRefPubMedGoogle Scholar
  20. 20.
    Bozkaya Y, Demirci NS, Kurtipek A, Erdem GU, Ozdemir NY, Zengin N. Clinicopathological and prognostic characteristics in patients with AFP-secreting gastric carcinoma. Mol Clinl Oncol. 2017;7:267–74.CrossRefGoogle Scholar
  21. 21.
    Zhao ZM, Wang J, Ugwuowo UC, Wang L, Townsend JP. Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. BMC Clin Pathol. 2018;18:3.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Jia C, Zhang Y, Xu J, Sun K. Experience in primary hepatic neuroendocrine tumor. Turk J Gastroenterol. 2012;23(5):546–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol. 1994;20:65–71.CrossRefPubMedGoogle Scholar
  24. 24.
    Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001;92:1101–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Yakup Bozkaya
    • 1
  • U. Aydın
    • 2
  • A. Avcı
    • 3
  • D. Tuncer
    • 4
  • E. Yılmaz
    • 5
  1. 1.Edirne State HospitalClinic of Medical OncologyEdirneTurkey
  2. 2.Department of General Surgery, Florence Nightingale HospitalBilim UniversityIstanbulTurkey
  3. 3.Department of Pathology, Ataturk Training and Research HospitalKatip Çelebi UniversityİzmirTurkey
  4. 4.Edirne State HospitalClinic of GastroenterologyEdirneTurkey
  5. 5.Department of RadiologyTrakya University Faculty of MedicineEdirneTurkey

Personalised recommendations